Immunocore (IMCR)
(Delayed Data from NSDQ)
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
Zacks News
5 Stocks With Recent Price Strength to Gain From July Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, FC, ASC, SNEX and ARLP.
Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 29%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 29.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has McKesson (MCK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for July 12th
by Zacks Equity Research
CCBG, IMCR and FSTX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2022.
Vertex (VRTX) to Buy ViaCyte to Speed Up VX-880 Program
by Zacks Equity Research
Vertex (VRTX) will acquire ViaCyte for $320 million in cash.
Here's Why "Trend" Investors Would Love Betting on Immunocore Holdings PLC Sponsored ADR (IMCR)
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Immunocore Holdings PLC Sponsored ADR (IMCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 36% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 35.9% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are Medical Stocks Lagging Galapagos (GLPG) This Year?
by Zacks Equity Research
Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Zacks.com featured highlights include Immunocore Holdings, United Fire Group, FTI Consulting, Consolidated Water and Huron Consulting
by Zacks Equity Research
Immunocore Holdings, United Fire Group, FTI Consulting, Consolidated Water and Huron Consulting are part of zacks Screen of the week article.
Here's What Could Help Immunocore Holdings PLC Sponsored ADR (IMCR) Maintain Its Recent Price Strength
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, UFCS, CWCO, HURN and FCN.
Seattle Genetics (SGEN) Moves 12.7% Higher: Will This Strength Last?
by Zacks Equity Research
Seattle Genetics (SGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health
by Zacks Equity Research
Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
by Zacks Equity Research
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
Wall Street Analysts See an 80% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to an 80.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study
by Zacks Equity Research
Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Strong execution across business segments, led by COVID-19 vaccinations and testing, drove Walgreens' (WBA) fiscal second-quarter top line.
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 135% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 134.8% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.